Patents by Inventor Christine Trumpfheller

Christine Trumpfheller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antigen binding molecules comprising anti-FAP clone 212
    Patent number: 12275794
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: April 15, 2025
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Harald Duerr, Christian Klein, Pablo Umana, Alexander Bujotzek, Joerg Zielonka, Christine Trumpfheller, Moritz Rapp, Marine Le Clech
  • Bispecific antigen binding molecules capable of specific binding to CD40 and to fap
    Patent number: 12145994
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: November 19, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Alexander Bujotzek, Harald Duerr, Guy Georges, Christian Klein, Stephane Leclair, Moritz Rapp, Eva Carina Sum, Christine Trumpfheller, Pablo Umaña
  • COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
    Publication number: 20240092856
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
  • COMBINATION THERAPY WITH FAP-TARGETED CD40 AGONISTS
    Publication number: 20230340154
    Abstract: The present invention relates to combination therapies employing FAP-targeted CD40 agonists, in particular bispecific antigen binding molecules comprising at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) and at least one antigen binding domain capable of specific binding to CD40, and radiotherapy.
    Type: Application
    Filed: May 16, 2023
    Publication date: October 26, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sara Labiano Alminana, Pedro Romero, Genrich Tolstonog, Christine Trumpfheller, Pablo Umana, Marie Catherine Vozenin
  • COMBINATION THERAPY WITH MODIFIED PBMCS AND AN IMMUNOCONJUGATE
    Publication number: 20230181712
    Abstract: The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the ?-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.
    Type: Application
    Filed: May 10, 2021
    Publication date: June 15, 2023
    Inventors: Pablo UMAÑA, Christian KLEIN, Christine TRUMPFHELLER, Valeria G. NICOLINI, Laura CODARRI DEAK, Scott LOUGHHEAD, Matthew BOOTY
  • BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING ANTI-FAP CLONE 212
    Publication number: 20220227878
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • Bispecific antigen binding molecules comprising anti-FAP clone 212
    Patent number: 11242396
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Harald Duerr, Christian Klein, Pablo Umana, Alexander Bujotzek, Joerg Zielonka, Christine Trumpfheller, Moritz Rapp, Marine Le Clech
  • BISPECIFIC ANTIGEN BINDING MOLECULES WITH TRIVALENT BINDING TO CD40
    Publication number: 20210292426
    Abstract: The invention relates to novel bispecific antigen binding molecules with trivalent binding to CD40 and monovalent binding to a target cell antigen and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: March 31, 2021
    Publication date: September 23, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald DUERR, Moritz RAPP, Christine TRUMPFHELLER, Pablo UMANA
  • NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP
    Publication number: 20210188992
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: February 18, 2021
    Publication date: June 24, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA
  • Bispecific antigen binding molecules comprising anti-FAP clone 212
    Publication number: 20200190207
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP
    Publication number: 20180340030
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: April 3, 2018
    Publication date: November 29, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Alexander BUJOTZEK, Harald DUERR, Guy GEORGES, Christian KLEIN, Stephane LECLAIR, Moritz RAPP, Eva Carina SUM, Christine TRUMPFHELLER, Pablo UMAÑA
  • Alkyl ethanolamines for the control of mycobacteria in functional fluid
    Publication number: 20050107270
    Abstract: An antimicrobial composition for inhibiting the growth of Mycobacteria in industrial fluids is provided.
    Type: Application
    Filed: July 8, 2004
    Publication date: May 19, 2005
    Inventors: Michael Gernon, Conor Dowling, Christine Trumpfheller
  • Reactive amine catalysts for use in pucb foundry binder
    Publication number: 20050004257
    Abstract: The present invention relates a reactive tertiary amine catalyst used in a phenolic urethane cold box process. Through the use of a reactive tertiary amine, the problems associated with vaporous amine waste streams can be eliminated. Some typical reactive tertiary amine catalysts that are useful in the present invention include 1-dimethylamino-2-propanol (DMA-2P), monoethanolamine and dimethylaminopropylamine (DMAPA).
    Type: Application
    Filed: July 12, 2004
    Publication date: January 6, 2005
    Inventors: Michael Gernon, Christine Trumpfheller, Bobby Picker